Rebel Medicine

Rebel Medicine is a private, preclinical-stage biotechnology company developing novel, extended-release local anesthetics to address the opioid crisis in post-operative pain management. The company's core technology platform enables the formulation of bupivacaine into long-acting gels and solutions, with its lead asset, Alevatrix™, having completed a Pre-IND meeting. Backed by non-dilutive grant funding from the NSF and NIH, Rebel aims to establish a new standard of care in loco-regional anesthesia that minimizes or eliminates the need for systemic opioids after surgery.

Proprietary drug delivery platform for creating extended-release formulations of local anesthetics, including an injectable gel technology and a solution-based system.

The market for long-acting local anesthetics is competitive, with an existing marketed product (liposomal bupivacaine) and other companies developing novel formulations. Rebel must demonstrate clear differentiation in duration of effect, safety profile, ease of administration, or cost to secure a meaningful market position.